IL222683B - Composition of sustained-release methotrexate as a disease-adapted anti-inflammatory and anticancer agent - Google Patents
Composition of sustained-release methotrexate as a disease-adapted anti-inflammatory and anticancer agentInfo
- Publication number
- IL222683B IL222683B IL222683A IL22268312A IL222683B IL 222683 B IL222683 B IL 222683B IL 222683 A IL222683 A IL 222683A IL 22268312 A IL22268312 A IL 22268312A IL 222683 B IL222683 B IL 222683B
- Authority
- IL
- Israel
- Prior art keywords
- dmard
- methotrexate
- disease
- sustained release
- release formulation
- Prior art date
Links
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 title 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000002988 disease modifying antirheumatic drug Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 229960000485 methotrexate Drugs 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33454610P | 2010-05-13 | 2010-05-13 | |
| US12/914,944 US9770414B2 (en) | 2010-05-13 | 2010-10-28 | Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent |
| PCT/US2011/036328 WO2011143484A1 (en) | 2010-05-13 | 2011-05-12 | A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL222683A0 IL222683A0 (en) | 2012-12-31 |
| IL222683B true IL222683B (en) | 2018-04-30 |
Family
ID=44911988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL222683A IL222683B (en) | 2010-05-13 | 2012-10-25 | Composition of sustained-release methotrexate as a disease-adapted anti-inflammatory and anticancer agent |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9770414B2 (enExample) |
| EP (1) | EP2568962B1 (enExample) |
| JP (3) | JP5980775B2 (enExample) |
| CN (1) | CN103002877B (enExample) |
| IL (1) | IL222683B (enExample) |
| WO (1) | WO2011143484A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104427976B (zh) | 2012-05-10 | 2018-04-24 | 佩因拉佛姆有限公司 | 疏水的活性成分的储库制剂及其制备方法 |
| HRP20230655T1 (hr) | 2012-07-05 | 2023-10-13 | Taiwan Liposome Company, Ltd. | Metode liječenja artritisa |
| WO2015147018A1 (ja) * | 2014-03-28 | 2015-10-01 | テルモ株式会社 | 炎症性自己免疫疾患治療用の注射用水性製剤 |
| WO2015183213A1 (en) * | 2014-05-28 | 2015-12-03 | Onko İlaç Sanayi̇ Ve Ti̇caret A. Ş. | Pharmaceutical dosage forms containing n-[4-[[(2,4-diamino-6-pteridinyl)methyl] methylamino] benzoyl]-l- glutamic acid and n-[4-[[(2-amino-3,4- dihydro -4-oxo-6- pteridinyl) methyl] methyl amino] benzoyl]-l-glutamic acid |
| CA2991921C (en) | 2014-07-30 | 2023-08-08 | Massachusetts Eye And Ear Infirmary | Methotrexate for proliferative vitreoretinopathy |
| BR112017012289B1 (pt) * | 2014-12-12 | 2022-11-16 | Motejo. Ltd | Agente para injeção hipodérmica |
| JP5774190B1 (ja) * | 2014-12-12 | 2015-09-09 | ジーンメディカル株式会社 | 皮下注射用剤及び皮下注射用剤を含有する注射器の製造方法 |
| WO2017004136A1 (en) | 2015-06-30 | 2017-01-05 | Tela Bio, Inc. | Corner-lock stitch patterns |
| WO2017015421A1 (en) | 2015-07-21 | 2017-01-26 | Tela Bio, Inc. | Compliance control stitching in substrate materials |
| DK3383482T3 (da) | 2015-11-24 | 2023-04-11 | Massachusetts Inst Technology | Systemer og fremgangsmåder til forebyggelse, mildnelse og/eller behandling af demens |
| WO2017189772A1 (en) | 2016-04-26 | 2017-11-02 | Tela Bio, Inc. | Hernia repair grafts having anti-adhesion barriers |
| EA201990473A1 (ru) * | 2016-08-12 | 2019-07-31 | Эл.И.Эй.Эф. ХОЛДИНГС ГРУП ЭлЭлСи | Полиглутамированные антифолаты и их применение |
| WO2018031967A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| WO2018031980A1 (en) | 2016-08-12 | 2018-02-15 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| US10279192B2 (en) | 2016-11-17 | 2019-05-07 | Cognito Therapeutics, Inc. | Methods and systems for neural stimulation via visual stimulation |
| KR102069680B1 (ko) * | 2017-03-02 | 2020-01-23 | 단디바이오사이언스 주식회사 | 면역억제인자 제어물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물 |
| WO2019074637A1 (en) | 2017-10-10 | 2019-04-18 | Massachusetts Institute Of Technology | SYSTEMS AND METHODS FOR PREVENTION, MITIGATION AND / OR TREATMENT OF DEMENTIA |
| US10960225B2 (en) | 2017-10-10 | 2021-03-30 | Massachusetts Institute Of Technology | Systems and methods for preventing, mitigating, and/or treating dementia via visual stimulation that binds higher order brain regions, reduces neurodegeneration and neuroinflammation, and improves cognitive function |
| WO2019099560A1 (en) | 2017-11-14 | 2019-05-23 | The Schepens Eye Research Institute, Inc. | Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| CN108553420A (zh) * | 2017-11-20 | 2018-09-21 | 平顶山学院 | 一种口服甲氨蝶呤脂质体及其制备方法 |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| WO2019157148A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749311A4 (en) * | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | PEMETREXED POLYGLUTAMATE GAMMA COMPOSITIONS AND THEIR USES |
| US12076402B2 (en) | 2018-02-07 | 2024-09-03 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated antifolates and uses thereof |
| CA3090506A1 (en) * | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated tetrahydrofolates and uses thereof |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| EP3749312A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| CN111954529A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化氨甲蝶呤及其用途 |
| US11779584B2 (en) * | 2018-02-07 | 2023-10-10 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated pemetrexed and uses thereof |
| WO2019157123A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| EP3749318A4 (en) | 2018-02-07 | 2022-07-06 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMATED RALTITREXED AND ITS USES |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| US11771700B2 (en) | 2018-02-14 | 2023-10-03 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| EP3752156A4 (en) | 2018-02-14 | 2021-10-27 | L.E.A.F Holdings Group LLC | GAMMA-POLYGLUTAMIZED PRALATREXATE AND USES THEREOF |
| CN111936145A (zh) | 2018-02-14 | 2020-11-13 | L.E.A.F.控股集团公司 | γ聚谷氨酸化氨甲蝶呤及其用途 |
| EP3761963B1 (en) | 2018-03-09 | 2025-01-22 | Tela Bio, Inc. | Surgical repair graft |
| US11446130B2 (en) | 2019-03-08 | 2022-09-20 | Tela Bio, Inc. | Textured medical textiles |
| CN110269939A (zh) * | 2019-03-12 | 2019-09-24 | 武汉愔紫生物科技有限公司 | 一种治疗真菌分泌蛋白介导的炎症疾病标志物的药物、药物组合物、用途及其使用方法 |
| AU2021225926A1 (en) | 2020-02-26 | 2022-10-20 | Case Western Reserve University | Compositions and methods for treating misfolded protein ocular disorders |
| WO2021216957A1 (en) * | 2020-04-23 | 2021-10-28 | Massachusetts Institute Of Technology | Systems, devices, and methods for gamma entrainment using sensory stimuli to alleviate cognitive deficits and/or neuroinflammation induced by chemotherapy agents |
| CN114249731B (zh) * | 2020-09-24 | 2023-09-29 | 南京海润医药有限公司 | 一种甲氨蝶呤中间体的精制方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4565696A (en) * | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| GB8704171D0 (en) * | 1987-02-23 | 1987-04-01 | Clayton Found Res | Multivesicular liposomes |
| US5723147A (en) * | 1987-02-23 | 1998-03-03 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| US5807572A (en) * | 1988-02-18 | 1998-09-15 | Depotech Corporation | Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride |
| US5422120A (en) | 1988-05-30 | 1995-06-06 | Depotech Corporation | Heterovesicular liposomes |
| NZ237464A (en) * | 1990-03-21 | 1995-02-24 | Depotech Corp | Liposomes with at least two separate chambers encapsulating two separate biologically active substances |
| EP0695169B1 (en) | 1993-04-22 | 2002-11-20 | SkyePharma Inc. | Multivesicular cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use |
| JP3002702B2 (ja) | 1993-11-16 | 2000-01-24 | スカイファーム インコーポレーテッド | 活性物質の制御放出を有する小胞 |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| US5891467A (en) * | 1997-01-31 | 1999-04-06 | Depotech Corporation | Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| US6306432B1 (en) * | 1997-09-08 | 2001-10-23 | Chiron Corporation | High and low load formulations of IGF-I in multivesicular liposomes |
| AU1307499A (en) * | 1997-11-05 | 1999-05-24 | Biozone Laboratories, Inc. | Enhanced infant formula containing liposome encapsulated nutrients and agents |
| JP4575592B2 (ja) | 1997-11-14 | 2010-11-04 | パシラ ファーマシューティカルズ インコーポレーテッド | 多小胞リポソームの製造 |
| PL367102A1 (en) * | 2001-05-02 | 2005-02-21 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
| AUPR593101A0 (en) * | 2001-06-26 | 2001-07-19 | Council Of The Queensland Institute Of Medical Research, The | Cytomegalovirus t cell epitopes |
| US8043602B2 (en) * | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US20040176381A1 (en) * | 2003-03-06 | 2004-09-09 | Walsh Michael J. | Methotrexate compliance packaging |
| US6921667B2 (en) * | 2003-03-07 | 2005-07-26 | Prometheus Laboratories, Inc. | Methods for direct detection of individual methotrexate metabolites |
| ATE502630T1 (de) * | 2004-07-16 | 2011-04-15 | Kyorin Seiyaku Kk | Verfahren zur effektiven anwendung eines medikaments und verfahren zur prävention von nebenwirkungen |
| WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| US20060116334A1 (en) * | 2004-12-01 | 2006-06-01 | Curt Hendrix | Folate based composition for treatment of the cardiovascular system |
| WO2006122414A1 (en) | 2005-05-17 | 2006-11-23 | Matregen Corp. | Depot for sustained and controlled delivery of methotrexate |
| JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
| EP2040674B1 (en) * | 2006-05-18 | 2010-07-07 | MediGene AG | Cationic liposomal preparations for the treatment of rheumatoid arthritis |
| DE102006033837A1 (de) | 2006-07-21 | 2008-01-31 | Medac Gesellschaft für klinische Spezialpräparate m.b.H | Konzentrierte Methotrexat-Lösungen |
| WO2008030818A2 (en) | 2006-09-05 | 2008-03-13 | Mebiopharm Co., Ltd. | Novel liposome compositions |
| US20080075807A1 (en) * | 2006-09-22 | 2008-03-27 | Baldwin Cheryl J | Methods Of Fortifying Foods With Vitamin D And Food Products Thereof |
| GB2443738A (en) | 2006-11-09 | 2008-05-14 | Proprius Pharmaceuticals Inc | A sustained release methotrexate composition and methods of use thereof |
| US8329220B2 (en) | 2007-08-24 | 2012-12-11 | Aegis Therapeutics, Llc | Controlled release formulations |
| CA2710333A1 (en) * | 2008-01-03 | 2009-07-09 | Abbott Biotechnology Ltd. | Predicting long-term efficacy of a compound in the treatment of psoriasis |
-
2010
- 2010-10-28 US US12/914,944 patent/US9770414B2/en active Active
-
2011
- 2011-05-12 CN CN201180023882.8A patent/CN103002877B/zh active Active
- 2011-05-12 JP JP2013510313A patent/JP5980775B2/ja active Active
- 2011-05-12 WO PCT/US2011/036328 patent/WO2011143484A1/en not_active Ceased
- 2011-05-12 EP EP11781306.3A patent/EP2568962B1/en active Active
-
2012
- 2012-10-25 IL IL222683A patent/IL222683B/en active IP Right Grant
-
2013
- 2013-03-05 US US13/786,323 patent/US10028911B2/en active Active
- 2013-03-05 US US13/786,368 patent/US20130183371A1/en not_active Abandoned
-
2015
- 2015-09-25 JP JP2015188829A patent/JP6263508B2/ja active Active
-
2017
- 2017-01-27 JP JP2017013045A patent/JP2017071652A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP2568962B1 (en) | 2017-11-29 |
| CN103002877A (zh) | 2013-03-27 |
| JP2017071652A (ja) | 2017-04-13 |
| JP5980775B2 (ja) | 2016-08-31 |
| US20130183371A1 (en) | 2013-07-18 |
| US10028911B2 (en) | 2018-07-24 |
| US9770414B2 (en) | 2017-09-26 |
| US20110280932A1 (en) | 2011-11-17 |
| US20130183370A1 (en) | 2013-07-18 |
| IL222683A0 (en) | 2012-12-31 |
| EP2568962A4 (en) | 2014-06-18 |
| WO2011143484A1 (en) | 2011-11-17 |
| CN103002877B (zh) | 2017-07-21 |
| JP2013526545A (ja) | 2013-06-24 |
| EP2568962A1 (en) | 2013-03-20 |
| JP6263508B2 (ja) | 2018-01-17 |
| JP2015232049A (ja) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL222683A0 (en) | A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent | |
| ZA201808498B (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| PT2493474T (pt) | Métodos e composições para libertação prolongada de fármacos | |
| PL3772354T3 (pl) | Kompozycja mikrosfer rysperydonu o przedłużonym uwalnianiu | |
| EP2521553A4 (en) | METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS | |
| EP2615913A4 (en) | EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS CONTAINING PREGABALIN | |
| IL231381A0 (en) | History of aminopyrimidines, their preparation and pharmaceutical preparations containing them | |
| EP2623505A4 (en) | (AZA) INDOLIZINE DERIVATIVE AND ITS PHARMACEUTICAL USE | |
| GB201104473D0 (en) | Improved pharmaceutical compositions and methods of delivery | |
| PT2655375E (pt) | Derivados de pirimidinona, sua preparação e sua utilização farmacêutica | |
| IL221043A0 (en) | Modified release formulation and methods of use | |
| AP3441A (en) | Pharmaceutical compositions comprising hydromorphone and naloxone | |
| PL2793865T3 (pl) | Kompozycje farmaceutyczne mikrosfer tryptoreliny | |
| ZA201405265B (en) | Derivatives of aza adamantane and uses thereof | |
| IL234931A0 (en) | Stable immediate-release oral pharmaceutical preparations containing prasugrel | |
| IL224191A (en) | Compositions of vitamin d and cmc epi-14 analogues | |
| EP2701689A4 (en) | PHARMACEUTICAL COMPOSITIONS OF RALTEEGRAVIR, METHODS OF PREPARATION AND USE THEREOF | |
| HK1183246A (en) | A sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (dmard) and an anti-cancer agent | |
| SG11201404915SA (en) | Sustained release oral solid preparation | |
| AP3382A (en) | Tuberculosis drug based on 4-thioureido-iminomethylpyridinium perchlorate: method of preparation andtreatment | |
| GB201001335D0 (en) | Drug release formulations | |
| EP2525660A4 (en) | FORMULATION WITH MODIFIED RELEASE AND USE METHOD | |
| GB201223447D0 (en) | Conjugate compounds for targeted drug deliver and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |